| 9.02 0.73 (8.81%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.87  |
1-year : | 12.7 |
| Resists | First : | 9.31 |
Second : | 10.87 |
| Pivot price | 7.85 |
|||
| Supports | First : | 7.88 |
Second : | 7 |
| MAs | MA(5) : | 8.32 |
MA(20) : | 7.75 |
| MA(100) : | 8.81  |
MA(250) : | 10.36 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 81.7 |
| RSI | RSI(14): 65.4 |
|||
| 52-week | High : | 14.86 | Low : | 7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BBOT ] has closed above the upper band by 19.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.32 - 9.36 | 9.36 - 9.39 |
| Low: | 8.31 - 8.35 | 8.35 - 8.38 |
| Close: | 8.94 - 9.02 | 9.02 - 9.08 |
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Wed, 08 Jul 2026
JPMorgan initiates BridgeBio Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Mon, 06 Jul 2026
Cormorant funds restructure 22.3% BridgeBio Oncology (BBOT) stake, add lock-up - Stock Titan
Mon, 06 Jul 2026
Cormorant funds tied to BBOT (NASDAQ: BBOT) receive 4.53M shares in internal distribution - Stock Titan
Tue, 30 Jun 2026
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
Fri, 26 Jun 2026
Price to book forward of BridgeBio Oncology Therapeutics, Inc. – NASDAQ:BBOT - TradingView
Thu, 11 Jun 2026
BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Progresses Pipeline - Return On Capital - lwvtexas.org
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 27.1 (%) |
| Held by Institutions | 68.8 (%) |
| Shares Short | 3,940 (K) |
| Shares Short P.Month | 3,280 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.3 % |
| Return on Equity (ttm) | -62.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -130 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -4.7 |
| PEG Ratio | 0 |
| Price to Book value | 1.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|